Qsemble Capital Management LP Takes $1.69 Million Position in Insmed Incorporated (NASDAQ:INSM)

Qsemble Capital Management LP acquired a new position in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 23,155 shares of the biopharmaceutical company's stock, valued at approximately $1,690,000.

Other large investors have also added to or reduced their stakes in the company. V Square Quantitative Management LLC bought a new position in shares of Insmed during the 3rd quarter valued at approximately $30,000. EntryPoint Capital LLC purchased a new stake in Insmed in the first quarter worth $33,000. GAMMA Investing LLC raised its stake in shares of Insmed by 71.3% in the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock valued at $39,000 after buying an additional 224 shares during the period. First Horizon Advisors Inc. raised its stake in shares of Insmed by 83.4% in the second quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 287 shares during the period. Finally, Exchange Traded Concepts LLC lifted its position in shares of Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company's stock valued at $55,000 after buying an additional 627 shares during the last quarter.

Insider Activity at Insmed

In other Insmed news, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction that occurred on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the transaction, the insider now directly owns 106,134 shares of the company's stock, valued at approximately $7,951,559.28. This trade represents a 11.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the company's stock in a transaction on Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the sale, the insider now directly owns 67,856 shares of the company's stock, valued at $5,045,093.60. This trade represents a 29.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock valued at $5,765,446 over the last 90 days. 4.60% of the stock is owned by insiders.

Insmed Price Performance

Shares of INSM stock traded up $1.59 during trading on Tuesday, hitting $75.68. The company had a trading volume of 1,104,500 shares, compared to its average volume of 2,235,838. The stock's 50-day moving average is $72.05 and its two-hundred day moving average is $66.93. The stock has a market capitalization of $13.54 billion, a price-to-earnings ratio of -13.35 and a beta of 1.12. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The firm had revenue of $93.40 million for the quarter, compared to analysts' expectations of $93.36 million. During the same quarter last year, the firm earned ($1.10) earnings per share. Insmed's revenue was up 18.1% on a year-over-year basis. As a group, analysts predict that Insmed Incorporated will post -5.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on INSM shares. UBS Group boosted their price objective on Insmed from $78.00 to $84.00 and gave the company a "buy" rating in a research note on Friday, August 9th. JPMorgan Chase & Co. boosted their price target on shares of Insmed from $74.00 to $83.00 and gave the company an "overweight" rating in a research report on Friday. StockNews.com cut shares of Insmed from a "hold" rating to a "sell" rating in a research note on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Insmed in a research note on Monday, September 9th. Finally, Truist Financial reissued a "buy" rating and set a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Insmed presently has an average rating of "Moderate Buy" and a consensus price target of $83.67.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.